Market cap
$473m
Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.
Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.
We paid Takeda an upfront license fee of $7.0 million in October 2022 , and it is eligible to receive potential future milestone payments of up to $287.3 million upon our achievement of certain regulatory and commercial milestones over the course of the exclusive license agreement, as well as tiered royalty payments for any net sales of alisertib. Results of Operations Three Months Ended June 30, 2026 Compared to Three Months Ended June 30, 2025 Total revenue: Total revenue for the three months ended June 30, 2026 was approximately $56.5 million, compared to $52.4 million for the three months ended June 30, 2025. …PUMA BIOTECHNOLOGY, INC., 10-Q, period ended 2026-06-30, filed 2026-08-06